Key result
Captopril reduces blood pressure by ~18% at 3 days in Bartter's syndrome.
Why the study?
This study evaluated the effects of captopril on blood pressure, renal function, electrolyte balance, and the renin-angiotensin system in patients with Bartter's syndrome.
Does captopril 25 mg t.i.d. affect blood pressure, renal function, electrolyte balance, and the renin-angiotensin system in patients with Bartter's syndrome?
Does captopril 25 mg t.i.d. affect blood pressure, renal function, electrolyte balance, and the renin-angiotensin system in patients with Bartter's syndrome?
In patients with Bartter's syndrome, captopril induces immediate and sustained blood pressure reduction and marked renal vasodilation without affecting glomerular filtration rate or potassium balance.
Answers are grounded in this paper and cite their sources.
May support ACEI consideration in Bartter's syndrome; leaves open confirmation in controlled trials.
3 patients with Bartter's syndrome were studied under metabolic ward conditions before and during administration of captopril 25 mg t.i.d. The drug induced an immediate and sustained reduction of blood pressure (by 14 and 18% after 1 h and 3 days, respectively) with no change in heart rate. During treatment renal plasma flow increased by 29%, but the glomerular filtration rate was unchanged. Renal vascular resistance decreased by 41%. There was an increase in urinary sodium excretion with a corresponding reduction of body weight. The potassium balance was not affected. The concentration of angiotensin II became normal but the plasma renin concentration rose tenfold. Plasma renin substrate, initially rather low, was further reduced. The blood pressure responsiveness to angiotensin II increased without being completely normalized. An abnormal production of vasodilating prostaglandins is thought to be an important feature of Bartter's syndrome. Our findings, notably the marked renal vasodilatation, may reflect the effect of these prostaglandins when unopposed by an increased angiotensin II production.
No takes yet. Share an insight, caveat, or question.
Aurell et al. (2008) studied Bartter's syndrome (n=3). Captopril vs. Baseline (pre-treatment) was evaluated on Blood pressure, renal function, electrolyte balance, and renin-angiotensin system parameters. Captopril 25 mg t.i.d. reduced blood pressure by 14% at 1 h and 18% at 3 days, increased renal plasma flow by 29%, and decreased renal vascular resistance by 41% in Bartter's syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: